Abstract
Introduction
The quadrivalent inactivated split-virion influenza vaccine (QIV; VaxigripTetra®) was initially licensed in South Korea in 2017 for immunization against seasonal influenza in those aged ≥ 3 years, with the indicated age subsequently lowered to include those aged ≥ 6 months in 2018. Here, to comply with South Korean licensure requirements, we undertook a post-marketing surveillance study to assess the safety of QIV in children aged 6–35 months (i.e., extension of the previous age indication to include these young children) in routine clinical practice.
Methods
A multicenter, observational, active safety surveillance of children aged 6–35 months who received a single dose of QIV during a routine healthcare visit was undertaken in South Korea from 15 June 2018 to 14 June 2022. Solicited adverse events (AEs) and unsolicited non-serious AEs were recorded in diary cards, with serious adverse events (SAEs) notified to study investigators.
Results
This safety analysis included 676 participants. No AEs led to study termination, and no SAEs were reported. The most frequent solicited injection site reaction was pain in both the ≤ 23-month (12.2% [55/450]) and ≥ 24-month (15.5% [35/226]) age groups. The most frequent solicited systemic reactions were pyrexia and somnolence in the ≤ 23-month age group (6.0% [27/450] each), and malaise (10.6% [24/226]) in the ≥ 24-month age group. Overall, 208 (30.8%) participants experienced 339 unsolicited non-serious AEs, with nasopharyngitis the most common (14.1% [95/676]), and nearly all events (98.8% [335/339]) were considered unrelated to QIV. Grade 3 solicited reactions and unsolicited non-serious AEs were reported in five (0.7%) and three (0.4%) participants, respectively, all of whom recovered by day 7 after vaccination.
Conclusion
This active safety surveillance study confirms that QIV is well tolerated in children aged 6–35 months in routine clinical practice in South Korea. There were no safety concerns observed in these young children.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
VaxigripTetra® (Sanofi), quadrivalent inactivated split-virion influenza vaccine (QIV), is now licensed for immunization against seasonal influenza in individuals aged ≥ 6 months in South Korea. |
A multicenter, observational, active safety surveillance study of QIV administered to children aged 6–35 months in routine clinical practice was undertaken to comply with South Korean licensure requirements. |
QIV had an acceptable safety profile in children aged 6–35 months and was well tolerated. |
There were no safety concerns identified, confirming the safety profile of QIV in young South Korean children in routine clinical practice. |
Introduction
The global burden of influenza in children aged under 5 years is substantial, with estimates prior to the COVID-19 pandemic suggesting 109.5 million influenza virus episodes and about 870,000 associated hospitalizations in 2018 alone [1]. Moreover, 28,000–111,500 deaths annually in these young children may be attributable to influenza [2]. In South Korea, seasonal influenza is typically associated with a range of about 500–5300 excess deaths across all age groups annually, and a mortality rate of 2.0–18.8 per 100,000 people [3,4,5]. The World Health Organization (WHO) recommends that annual influenza vaccination be considered for children, in addition to other groups at risk of severe influenza-associated disease and death, and healthcare workers [6].
The quadrivalent inactivated split-virion influenza vaccine (QIV), VaxigripTetra® (Sanofi), was licensed for immunization against seasonal influenza in those aged ≥ 3 years in South Korea in June 2017. The inclusion of an additional influenza B strain in QIV relative to trivalent influenza vaccines offers broader protection against seasonal influenza, with comparable safety and immunogenicity [7, 8]. Subsequently, the indicated age for QIV was lowered a year later (June 2018) to include those aged ≥ 6 months. Two post-marketing surveillance studies were undertaken to assess the safety of QIV in routine clinical practice to comply with South Korean licensure requirements [9]. The first study (GQM13) was conducted in participants aged ≥ 3 years in line with the initial indicated age group and has been published [10]. Here, we describe the second post-marketing safety surveillance study (GQM15) in the new indicated age group, children aged 6–35 months.
Methods
Study Design/Participants
This was an open, multicenter, observational study which conducted active safety surveillance for QIV (VaxigripTetra®, Sanofi) between 15 June 2018 (date of approval for the extended indication) and 14 June 2022. The study took place under conditions of routine clinical practice at 12 sites in South Korea, using similar methodology as described in the first post-marketing safety surveillance study of QIV in individuals aged ≥ 3 years (GQM13) [10]. Briefly, in the current study, children aged 6–35 months who had received a single dose of QIV according to the approved local product labeling, during a routine healthcare visit were enrolled. Children who had participated (within 4 weeks preceding enrollment) or had planned participation in another clinical study (while in the current study) were excluded. No vaccine was provided specifically for this study, and participants were enrolled after receipt of QIV as part of routine vaccination. Enrolled participants were followed up for 21–28 days after vaccination. The children may have received two doses of influenza vaccine, depending on their previous vaccination history and, if so, were only followed after one dose (either first or second vaccination).
The study was undertaken in compliance with the International Conference on Harmonization (ICH) guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki. The protocol and amendments were approved by applicable independent ethics committees/institutional review boards and the regulatory agency as per local regulations. Signed informed consent from the parent or the child’s legal representative was required before inclusion in this study.
Safety Surveillance
The parents or child’s legal representatives were given diary cards, digital thermometers, and flexible rulers, and instructed how to use these to record body temperature, and solicited adverse reactions (injection site and systemic reactions) and unsolicited adverse events (AEs), including their intensity (grade 1–3), and any action taken to treat them. Solicited adverse reactions were recorded up to 7 days after vaccination, with the list of solicited reactions adjusted by age group as per the ICH E11 definitions for infants/toddlers (≤ 23 months) and children (≥ 24 months) [11]. For solicited injection site reactions, these were induration (for those aged ≤ 23 months only), ecchymosis, erythema, pain, and swelling. For solicited systemic reactions, these were crying, decreased appetite, irritability, pyrexia, somnolence, and vomiting in those aged ≤ 23 months; and chills, headache, malaise, myalgia, and pyrexia in those aged ≥ 24 months.
Unsolicited non-serious AEs that occurred up to 21–28 days after vaccination were recorded in a separate space within the diary card, along with their size or intensity (grade 1–3) and any action taken to manage them. Serious adverse events (SAEs) were reported to the study investigators as and when they occurred throughout the study. The investigator assessed the causal relationship between the vaccine and each unsolicited non-serious AE and SAE (as per the South Korean Ministry of Food and Drug Safety [MFDS] guidelines).
Statistical Analysis
No statistical hypothesis was tested. The sample size justification and data analyses are the same as those described in the previous QIV safety surveillance study (GQM13) [10]. All data analyses were descriptive and performed on the safety analysis set, defined as participants who had regardless of their vaccination schedule received a dose of QIV. The sample size was based on the need to ensure at least 600 participants (600 vaccinations) would be evaluable, in accordance with South Korean MFDS guidelines. Assuming a 10% attrition rate for loss to follow-up or for invalid or incomplete case report forms, then 670 eligible participants were required to give a probability of 95% of observing any AE (at least one occurrence) with a true incidence of 0.45% or more, using the rule of three.
The data were summarized by number and percentage (and 95% confidence intervals, CIs) of participants reporting each safety event, with 95% CIs calculated using the exact binomial distribution (Clopper–Pearson method) for proportions and the normal approximation for quantitative data. Statistical assessments were performed with SAS version 9.2 or above (SAS Institute, Cary, NC, USA).
Results
Study Participants
A total of 682 participants were enrolled in the study (median 50 per center, range 6–209), six (0.9%) of whom were excluded from the safety analysis set: five received the study vaccine prior to the site initiating contract date, and one participant was lost to follow-up. Thus, 676 (99.1%) participants were included in the safety analysis set: 450 (67%) aged ≤ 23 months, and 226 (33%) aged ≥ 24 months. The participants demographics at baseline are summarized in Table 1.
Safety
The frequency of solicited adverse reactions and unsolicited non-serious AEs are summarized in Table 2. Injection site pain was the most frequently reported solicited injection site reaction in both the ≤ 23-month (12.2% [n = 55]) and ≥ 24-month (15.5% [n = 35]) age groups. Pyrexia and somnolence were the most frequently reported solicited systemic reactions in the ≤ 23-month age group (6.0% [n = 27] each), with malaise the most frequently reported in the ≥ 24-month age group (10.6% [n = 24]). The vast majority of solicited reactions (95.5% [322/337 events]) were reported 0–3 days after vaccination. There were six grade 3 solicited injection site and systemic reactions reported in five participants (pyrexia, n = 3; erythema, n = 1; irritability, n = 1; chills, n = 1). All participants recovered by day 7 after vaccination.
Overall, 339 unsolicited non-serious AEs were reported from 208 (30.8%) participants; nasopharyngitis was the most frequently reported with 103 nasopharyngitis events reported by 95 (14.1%) participants (Table 3). Pyrexia was the only grade 3 unsolicited non-serious AE (three events in three participants), and all participants recovered. Nearly all unsolicited non-serious AEs (98.8% [335/339 events]) were considered “unlikely” to be related to QIV. The four events considered to have a “possible” causal relationship with QIV were urticaria (n = 2), nasopharyngitis (n = 1) and rhinorrhea (n = 1). There were no SAEs or AEs leading to study termination reported.
Discussion
This post-marketing safety surveillance study confirms the safety of QIV in children aged 6–35 months in routine clinical practice in South Korea. No safety issues were identified, and no SAEs or AEs leading to study termination were reported during the 4-year surveillance period. The most frequently reported solicited reactions were injection site pain, pyrexia, somnolence, and malaise, and nasopharyngitis was the most frequently reported unsolicited non-serious AE. There were no notable differences in the overall frequency rates of solicited reactions between participants aged ≤ 23 months and those aged ≥ 24 months.
The overall safety profile of QIV observed in this study is at least generally consistent with the findings of three large-scale, phase III randomized, controlled, global clinical trials of QIVs (VaxigripTetra [Sanofi], Influvac Tetra [Abbott], and Fluarix Quadrivalent [GlaxoSmithKline], respectively) in children aged 6–35 months [12,13,14], as well those of a smaller, single-arm bridging study of another QIV (PT Bio Farma) in Indonesia that included this age group [15]. Notably, in the three global clinical studies, the overall safety profile of QIVs was shown to be comparable with that of the non-influenza control vaccines [12, 14], and aside from a slightly higher frequency of injection site reactions, with that of placebo also [13]. Our safety findings are also consistent with those of a wide range of clinical studies of QIV (VaxigripTetra) across age groups > 3 years, which have demonstrated favorable tolerability and safety, with reported safety events generally of mild or moderate severity [8, 16,17,18]. Our study further supports the overall safety profile of QIV (VaxigripTetra) observed in a number of enhanced safety surveillance studies conducted in routine practice in Europe (which included a small proportion of participants aged 6–35 months) [19,20,21,22,23].
Limitations of our study included the sample size chosen; this lacked sufficient numbers of participants to detect rare events. In addition, inherent to observational post-marketing surveillance study, there was no comparator or control agent, and as such the background rate of the events reported is unknown in the childhood population assessed. However, the advantage of this design is the generation of real-world data on the safety of QIV used in routine clinical practice.
Conclusion
Our post-marketing safety surveillance study confirms that QIV is well tolerated in children aged 6–35 months in routine clinical practice in South Korea and has an acceptable safety profile with no safety concerns.
References
Wang X, Li Y, O’Brien KL, et al. Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study. Lancet Glob Health. 2020;8(4):e497–510. https://doi.org/10.1016/S2214-109X(19)30545-5.
Nair H, Brooks WA, Katz M, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011;378(9807):1917–30. https://doi.org/10.1016/S0140-6736(11)61051-9.
Hong K, Sohn S, Chun BC. Estimating influenza-associated mortality in Korea: the 2009–2016 seasons. J Prev Med Public Health. 2019;52(5):308–15. https://doi.org/10.3961/jpmph.19.156.
Chungmin P, Gyehee L, Hyengil C, Jeongsuk S, Donghan L. Estimation of excess mortality associated with influenzas in Korea. In: Cheongju Korea Disease Control and Prevention Agency (KDCA). 2021. p. 1157–1161.
Park M, Wu P, Goldstein E, Joo Kim W, Cowling BJ. Influenza-associated excess mortality in South Korea. Am J Prev Med. 2016;50(4):e111–9. https://doi.org/10.1016/j.amepre.2015.09.028.
World Health Organization. Vaccines against influenza: WHO position paper—May 2022. Wkly Epidemiol Rec No. 19 2022. 97:185–208.
Gresset-Bourgeois V, Leventhal PS, Pepin S, et al. Quadrivalent inactivated influenza vaccine (VaxigripTetra). Expert Rev Vaccines. 2018;17(1):1–11. https://doi.org/10.1080/14760584.2018.1407650.
Choi WS, Noh JY, Lee J, et al. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18–60 years of age in the Republic of Korea. Hum Vaccin Immunother. 2018;14(3):587–92. https://doi.org/10.1080/21645515.2017.1381808.
Ministry of Food and Drug Safety (MFDS). Standard for re-examination of new drugs. Cheongju: Korean Ministry of Food and Drug Safety; 2020.
Lim S, Li X, Syrkina O, Fournier M. Post-marketing surveillance of a quadrivalent influenza vaccine (Vaxigrip Tetra) in South Korea. Infect Dis Ther. 2022;11(5):2035–43. https://doi.org/10.1007/s40121-022-00685-x.
European Medicines Agency (EMA): ICH Topic E 1. Clinical Investigation of Medicinal Products in the Paediatric Population. Step5. Note for guidance on clinical investigation of medicinal products in the paediatric population (CPMP/ICH/2711/99). 2001. https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-1.pdf. Accessed 9 Feb 2023.
Esposito S, Nauta J, Lapini G, Montomoli E, van de Witte S. Efficacy and safety of a quadrivalent influenza vaccine in children aged 6–35 months: a global, multiseasonal, controlled, randomized phase III study. Vaccine. 2022;40(18):2626–34. https://doi.org/10.1016/j.vaccine.2022.02.088.
Pepin S, Dupuy M, Borja-Tabora CFC, et al. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6–35 months: a multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres. Vaccine. 2019;37(13):1876–84. https://doi.org/10.1016/j.vaccine.2018.11.074.
Claeys C, Zaman K, Dbaibo G, et al. Prevention of vaccine-matched and mismatched influenza in children aged 6–35 months: a multinational randomised trial across five influenza seasons. Lancet Child Adolesc Health. 2018;2(5):338–49. https://doi.org/10.1016/S2352-4642(18)30062-2.
Dhamayanti M, Tarigan R, Fadlyana E, et al. Immunogenicity and safety of quadrivalent influenza HA vaccine in Indonesian children: an open-labeled, bridging, clinical study. Vaccine. 2020;38(5):993–1000. https://doi.org/10.1016/j.vaccine.2019.12.008.
Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, et al. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: a randomized, controlled, phase III trial. Vaccine. 2015;33(21):2485–92. https://doi.org/10.1016/j.vaccine.2015.03.065.
Thiem VD, Chabanon AL, Fournier M, et al. Safety of a quadrivalent influenza vaccine in Vietnamese healthy subjects aged 6 months and older. Hum Vaccin Immunother. 2021;17(3):690–3. https://doi.org/10.1080/21645515.2020.1795477.
Pepin S, Szymanski H, Rochin Kobashi IA, et al. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: a phase III randomized controlled study. Hum Vaccin Immunother. 2016;12(12):3072–8. https://doi.org/10.1080/21645515.2016.1212143.
Serradell L, Wague S, Moureau A, Nissila M, Chabanon AL. Enhanced passive safety surveillance of a trivalent and a quadrivalent influenza vaccine in Denmark and Finland during the 2018/2019 season. Hum Vaccin Immunother. 2021;17(4):1205–10. https://doi.org/10.1080/21645515.2020.1804247.
Chabanon AL, Wague S, Moureau A, Nissila M, Serradell L. Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019/20 influenza season. BMC Public Health. 2021;21(1):358. https://doi.org/10.1186/s12889-021-10378-8.
Gandhi-Banga S, Chabanon AL, Eymin C, Caroe T, Butler K, Moureau A. Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season. Hum Vaccin Immunother. 2019;15(9):2154–8. https://doi.org/10.1080/21645515.2019.1581538.
Gandhi-Banga S, Wague S, Shrestha A, et al. Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the influenza season 2021/22. Influenza Other Respir Viruses. 2023;17(1):e13071. https://doi.org/10.1111/irv.13071.
Syrkina O, Inamdar A, Wague S, et al. Enhanced passive safety surveillance of a quadrivalent inactivated split virion influenza vaccine in Finland during the influenza season 2020/21. BMC Public Health. 2022;22(1):1506. https://doi.org/10.1186/s12889-022-13898-z.
Acknowledgements
The authors would like to thank all participants of this study and their families, the primary investigators and their site staff.
Funding
The study was funded by Sanofi. The sponsor also provided support for the journal’s Rapid Service Fee.
Editorial Assistance
Editorial assistance with the preparation of the manuscript was provided by Richard Glover and Juliet George on behalf of inScience Communications, Springer Healthcare Ltd, Chester, UK and was funded by Sanofi. The authors also thank Yukie Kobayashi for assistance with study management, and Isabel Gregoire for editorial assistance and manuscript coordination on behalf of Sanofi.
Author Contributions
Olga Syrkina and Marion Fournier contributed to study concept/design, Sooyoun Shin was involved in data acquisition, and Sunho Choe, Oxana Talanova, Olga Syrkina and Marion Fournier contributed to data analysis and/or interpretation. All authors participated in the drafting and critical revision of this manuscript and approved the final version and are accountable for its accuracy and integrity.
Disclosures
All named authors are employees of Sanofi and may hold shares and/or stock options in the company.
Compliance with Ethics Guidelines
Signed informed consent by the parent or other legally acceptable representative was required for participation in the study. This study was conducted in accordance with the Good Epidemiological Practice guidelines. The protocol and amendments were approved by applicable independent ethics committees/institutional review boards and the regulatory agency as per local regulations. The institutional review board responsible for approving this study was the Hanil General Hospital, Seoul (HGH-2019-PMS-011), which initially approved the study on 25 September 2019. All further modifications were approved by this institutional review board before the implementation of any changes.
Data Availability
The data sets generated and/or analyzed during the current study, including the raw data, are not publicly available in order to safeguard the privacy of participants and the confidentiality and protection of their data, as well as protect commercially sensitive information. Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and data set specifications. Patient level data will be anonymized, and study documents will be redacted to protect the privacy of our trial participants. Further details on Sanofi’s data sharing criteria, including required permissions to access the data, eligible studies, and process for requesting access can be found at https://www.vivli.org/.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Choe, S., Talanova, O., Shin, S. et al. Post-Marketing Safety Surveillance of Quadrivalent Influenza Vaccine (VaxigripTetra) in Children Aged 6 to 35 Months in South Korea. Infect Dis Ther 12, 1715–1723 (2023). https://doi.org/10.1007/s40121-023-00825-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40121-023-00825-x